ERIS Lifesciences Ltd (ERIS) — FY26 Annual Report | 2 September 2026

ERIS Lifesciences Ltd reported FY26 revenue of ₹3,129 crore (8% YoY growth), EBITDA margin of 35.8% (73% YoY EBITDA growth), and PAT of ₹648 crore including a one-time ₹150 crore deferred tax benefit. The company expanded its Bhopal biologics facility (130+ million vials/year capacity) and invested ₹297 crore in FY26 capex toward biologics and injectables, part of a ₹750-800 crore plan through FY28. Domestic branded formulations revenue grew 11% YoY to ₹2,778 crore, contributing 89% of total revenue. Key growth drivers include insulin market share expansion (8% to 25%), GLP-1 leadership (Semaglutide ranked #1 by volume), and international revenue of ₹348 crore (7% YoY). Gross margin pressure (74.6%) was offset by operational leverage. The company maintains strong governance with 7 board meetings held, all directors compliant with independence criteria, and no material non-compliance except an 85-day delay in appointing an Independent Director post-December 2025. Shareholding remains concentrated at 53.92% promoter stake, with top institutional investors including HDFC Mutual Fund and Lilac Investments.